TY  - RPRT
TI  - Polyvalent immunoglobulins – Part 1: A rapid review
AU  - Bourgeois Jolyce
AU  - Fairon Nicolas
AU  - San Miguel Lorena
AB  - KCE Reports 327C (2019)

Immunoglobulins, which are produced from human plasma, are invaluable and costly medicines used to treat equally rare and sometimes very serious diseases. There is an ever increasing risk of shortage, both in Belgium and worldwide, which means that strategies must urgently be devised with a view to a better control of their supplies and optimisation of the way they are used.
T2  - KCE Reports
CY  - Brussels
PY  - 2019
LA  - English
M3  - Health Technology Assessment (HTA)
PB  - Belgian Health Care Knowledge Centre (KCE)
SN  - 327
VO  - D/2019/10.273/82
DO  - https://doi.org/10.57598/R327C
ER -